Saturday 19th of March 2022 01:00:56 PM

Bristol accuses AstraZeneca of violating Opdivo patents in lawsuit

Patent Litigation is shown on the photo using the text Andrii Dodonov/iStock via Getty Images
  • Bristol-Myers Squibb (NYSE:BMY) has filed a patent infringement lawsuit against AstraZeneca (NASDAQ:AZN) that argues that the U.K.-based pharma's cancer treatment Imfinzi (durvalumab) infringes on patents related to Opdivo (nivolumab).
  • The lawsuit was filed on Thursday in the U.S. District Court in Delaware.
  • Bristol alleges that Infinzi infringes on several Opdivo patents, including: Human Monoclonal Antibodies to Programmed Death Ligand 1 (PD-L1) ('505, '507 patent); and Cancer Immunotherapy by Disrupting PD-1/PD-L1 Signaling ('299 patent).
  • Opdivo is approved for many types of cancer, while Imfinzi is approved for small cell and non-small cell lung cancer.
  • Opdivo had 2021 sales of $~7.5B, while Imfinzi sales last year were ~$2.4B.
  • Read why Seeking Alpha contributor Cappuccino Finance says that Bristol (BMY) is a buy.


Top gainers today
Top losers today